Source / episode info
- **Episode:**63
- **Title:**Divine Intervention Episode 63 – Cardiac Pharm Part 3 (The Final Part)
- **Published:**2018-11-22
- Source:Episode page
One-liner
This episode covers the pharmacology of vasodilators (Nitroglycerin, Nitroprusside, Hydralazine), PDE inhibitors (PDE3/4/5) for various conditions, detailed lipid metabolism pathways (VLDL -> IDL -> LDL), statin mechanisms, and critical management pearls including magnesium toxicity and diabetic nephropathy.
High-yield summary
- Nitroglycerin: Primary mechanism is decreasing myocardial oxygen demand by acting as a potent venodilator, increasing venous capacitance, and reducing preload.
- PDE Inhibitors: PDE3 (e.g., Sildenafil) increases cGMP -> smooth muscle relaxation; PDE4 (e.g., Acapolar) increases cAMP -> bronchodilation; PDE5 (e.g., Tadalafil) increases cGMP -> erectile dysfunction/pulmonary hypertension treatment.
- Lipid Metabolism: LDL is cleared from the circulation primarily by binding to the LDL receptor on hepatocytes, a process enhanced by statins. VLDL synthesis involves cholesterol ester formation via ACAT and packaging with APOB100.
- Magnesium Management: High Mg levels decrease PTH release; low Mg levels increase PTH release (until critically low); hypomagnesemia must be corrected before calcium/potassium supplementation, as it impairs renal ion handling.
- Diabetic Nephropathy: Diabetic microalbuminuria requires an ACE inhibitor or ARB because Angiotensin II constricts the efferent arteriole, leading to increased glomerular hydrostatic pressure and hyperfiltration injury.
Learning objectives
- Differentiate the clinical uses and mechanisms of PDE3, PDE4, and PDE5 inhibitors.
- Explain the physiological consequences of high vs. low magnesium levels on PTH release and renal ion handling.
- Describe the metabolic pathway for lipoprotein synthesis (VLDL -> IDL -> LDL) and the role of key enzymes (ACAT, LPL).
- Identify the primary mechanism by which statins reduce circulating LDL cholesterol.
- Recognize the indications for ACE inhibitors/ARBs in diabetic nephropathy to prevent hyperfiltration injury.
Board exam buzzwords